For the first time in the 12-year history of the Rx and Illicit Drug Summit, the topic of overdose prevention centers took center stage on Thursday morning, with stakeholders involved with OPCs in the US convening for a panel.

At the Rx Summit on Wednesday, officials from the Drug Enforcement Administration (DEA) outlined the fentanyl crisis plaguing the United States and explained how the organizations fueling it are strengthening their operations—and how DEA is responding.

ONDCP Director Rahul Gupta, MD, MPH, MBA, FACP, announced during an Rx Summit plenary session on Wednesday that fentanyl combined with xylazine has been designated as an emerging threat to the United States.